Surgical Treatments for Shoulder Instability
Trial Summary
What is the purpose of this trial?
This is a pilot multi-centre, double blinded randomized controlled trial. The primary outcome of this pilot trial will be feasibility. Prior to conducting a large definitive trial, the investigators will conduct this pilot trial comparing arthroscopic Bankart repair with arthroscopic anatomic glenoid reconstruction (AAGR), evaluating recurrent dislocation rates and functional outcomes over a 24-month period. The feasibility objectives are: (1) to evaluate the investigators ability to recruit patients across multiple sites and (2) to assess study protocol adherence and ability to follow patients to 24 months. Clinical objectives for the pilot trial are exploratory only. The investigators wish to gather means and standard deviations for clinical outcomes to power their future definitive trial. The objectives of the definitive trial will include a comparison of patient-reported outcomes at the two-year post-operative time point, differences in recurrence rates, complication rates, functional shoulder assessments, and return to work/sport.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Anatomic Glenoid Reconstruction for shoulder instability?
Research shows that surgical procedures like the Bankart repair, which is part of Anatomic Glenoid Reconstruction, are effective for treating shoulder instability. Studies found that most patients regained shoulder stability and returned to their previous activity levels, with a high percentage experiencing satisfactory outcomes and no recurrent dislocations.12345
Is the surgical treatment for shoulder instability safe?
The surgical treatments for shoulder instability, including Arthroscopic Bankart Repair and Anatomic Glenoid Reconstruction, generally have a similar safety profile with low rates of complications like infection or nerve issues. Most patients regain normal shoulder stability, and specific techniques like using suture anchors have not shown additional complications.34678
How does the Anatomic Glenoid Reconstruction and Bankart Repair treatment differ from other treatments for shoulder instability?
The Anatomic Glenoid Reconstruction and Bankart Repair treatment is unique because it involves reattaching the labrum (a ring of cartilage) to the shoulder socket using suture anchors, which can be done arthroscopically (through small incisions) or through an open procedure. This approach helps restore shoulder stability and avoids complications associated with larger incisions, offering improved cosmetic results and outcomes similar to traditional open techniques.3591011
Research Team
Ivan Wong, MD
Principal Investigator
Nova Scotia Health Authority
Eligibility Criteria
This trial is for individuals with recurrent shoulder dislocations who have specific bone loss visible on imaging. It's not suitable for those with uncontrolled diabetes, pregnancy, severe illness, massive rotator cuff tears, certain levels of bone loss, posterior instability, shoulder paralysis, cancer, generalized laxity or previous surgery on the affected shoulder.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either arthroscopic Bankart repair or arthroscopic anatomic glenoid reconstruction (AAGR) for anterior shoulder instability
Follow-up
Participants are monitored for safety, recurrence of dislocation, and functional outcomes
Long-term Follow-up
Participants continue to be monitored for long-term outcomes and recurrence rates
Treatment Details
Interventions
- Anatomic Glenoid Reconstruction
- Bankart Repair
Anatomic Glenoid Reconstruction is already approved in European Union, United States for the following indications:
- Anterior shoulder instability
- Glenoid bone loss
- Recurrent shoulder dislocations
- Glenoid bone loss
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nova Scotia Health Authority
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator